| Bioactivity | Anizatrectinib (hTrkA-IN-1) is a potent and orally active inhibitor of TrkA kinase with an IC50 of 1.3 nM, compound 2 extracted from patent WO2015175788. Anizatrectinib can be used for the study of inflammatory disease, such as prostatitis, pelvic, et al[1]. |
| Name | Anizatrectinib |
| CAS | 1824664-89-2 |
| Formula | C29H32FN7O2 |
| Molar Mass | 529.61 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Shelley Allen, et al. 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor. Patent WO2015175788A1. |
Anizatrectinib
CAS: 1824664-89-2 F: C29H32FN7O2 W: 529.61
Anizatrectinib (hTrkA-IN-1) is a potent and orally active inhibitor of TrkA kinase with an IC50 of1.3 nM, compound 2 ext
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.